



Omega Pharma reports on share buy-back programme

Nazareth (Belgium) - 20 October 2011 (6:15 p.m. CET) (*). Omega Pharma (OME BB, OMEP.BR), the specialist in over-the-counter medicines and healthcare products, reports that it has acquired 99,242 treasury shares in the period from 12 to 20 October 2011.

The transactions follow on the decision by the board of directors of Omega Pharma on 2 September 2011 to activate its share buy-back programme for which authorization has been granted by the extraordinary shareholders meeting of 17 June 2011.

In the past seven trading days, the following numbers of shares have been acquired on NYSE Euronext Brussels through an intermediate, acting with a discretionary mandate:

Date	Number of shares acquired	Average price (in EUR)	Highest price (in EUR)	Lowest price (in EUR)	Total amount (in EUR)
12 October 2011	8,363	34.4669	34.510	34.300	288,246.68
13 October 2011	7,200	34.3786	34.470	34.300	247,525.92
14 October 2011	13,500	34.4369	34.500	34.350	464,898.15
17 October 2011	16,697	34.2198	34.450	34.100	571,368.00
18 October 2011	11,487	34.2212	34.350	34.050	393,098.92
19 October 2011	13,492	34.3583	34.420	34.175	463,562.18
20 October 2011	13,503	34.3021	34.420	34.170	463,181.26
12-20 October 2011	84,242	34.3283	34.510	34.050	2,891,881.12

In addition, and within the same programme and mandate, the following numbers of shares have been acquired in block trades, off exchange:

Date	Number of shares acquired	Price (in EUR)	Total amount (in EUR)
12 October 2011	15,000	34.44	516,600.00
12-20 October 2011	15,000	34.44	516,600.00

Combining both the trades on NYSE Euronext Brussels and the off exchange transactions, a total of 99,242 treasury shares have been acquired in the period from 12 to 20 October 2011 – or 2,501,120 treasury shares since the activation of the programme on 2 September 2011.

Prior to the activation of the programme, Omega Pharma already held 879,994 treasury shares. As a result of the transactions mentioned in the tables above, Omega Pharma now holds 3,381,114 treasury shares, representing 13.95% of the total number of shares outstanding.

For more information, please contact

Chris Van Raemdonck (Chris.vanraemdonck@omega-pharma.be)

Investor Relations - Omega Pharma

Direct line: 0032 9 381 0331 - Cell: 0032 499 58 55 31